Literature DB >> 7476271

Genotoxicity of 17 gyrase- and four mammalian topoisomerase II-poisons in prokaryotic and eukaryotic test systems.

S Albertini1, A A Chételat, B Miller, W Muster, E Pujadas, R Strobel, E Gocke.   

Abstract

The genotoxic potency of certain classes of topoisomerase II poisons is correlated with their affinity to the topoisomerase protein rather than with the presence of 'classical' structural alerts for DNA reactivity: bacterial topoisomerase II poisons (specifically named gyrase inhibitors) are highly genotoxic in prokaryotic systems; mammalian topoisomerase II poisons are potent mutagens/clastogens in eukaryotic systems. Studies with bacterial, lower eukaryotic and mammalian genotoxicity tests were performed to draw structure-activity conclusions and address risk-benefit considerations for the class of quinolone gyrase inhibitors. All 17 gyrase inhibitors investigated in this study showed genotoxic activity in Salmonella typhimurium strain TA102 and the SOS test. The genotoxic and the toxic activities increased in a highly parallel fashion from the parent compounds, nalidixic acid and oxolinic acid, to the new generation fluoroquinolones. Generally, the most potent fluoroquinolones also show clear-cut positive effects in eukaryotic test systems, although at concentrations 100-1000-fold higher than those effective in bacteria and also 100-1000-fold higher than the minimal genotoxic concentrations of antitumour topoisomerase II inhibitors (ellipticine, teniposide, mAMSA) used as reference compounds. However, subtle structural modifications of the quinolones can strongly diminish the preferential genotoxicity in the prokaryotic test systems.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7476271     DOI: 10.1093/mutage/10.4.343

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  9 in total

1.  Succession of pelagic marine bacteria during enrichment: a close look at cultivation-induced shifts.

Authors:  H Eilers; J Pernthaler; R Amann
Journal:  Appl Environ Microbiol       Date:  2000-11       Impact factor: 4.792

2.  Synthesis and structure-activity relationships of antimalarial 4-oxo-3-carboxyl quinolones.

Authors:  Yiqun Zhang; W Armand Guiguemde; Martina Sigal; Fangyi Zhu; Michele C Connelly; Solomon Nwaka; R Kiplin Guy
Journal:  Bioorg Med Chem       Date:  2010-02-11       Impact factor: 3.641

3.  Evaluating the genotoxicity of topoisomerase-targeted antibiotics.

Authors:  Daniel J Smart; Anthony M Lynch
Journal:  Mutagenesis       Date:  2011-12-07       Impact factor: 3.000

4.  Use of antibacterial agents To elucidate the etiology of juvenile oyster disease (JOD) in Crassostrea virginica and numerical dominance of an alpha-proteobacterium in JOD-affected animals.

Authors:  K J Boettcher; B J Barber; J T Singer
Journal:  Appl Environ Microbiol       Date:  1999-06       Impact factor: 4.792

5.  Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-α by macrophages: role of the DNA damage response.

Authors:  Kyle L Poulsen; Jesus Olivero-Verbel; Kevin M Beggs; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2014-05-09       Impact factor: 4.030

Review 6.  New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents.

Authors:  Katerina Gurova
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

7.  Mutagenesis and evolution of sulfated antibodies using an expanded genetic code.

Authors:  Chang C Liu; Hyeryun Choe; Michael Farzan; Vaughn V Smider; Peter G Schultz
Journal:  Biochemistry       Date:  2009-09-22       Impact factor: 3.162

8.  Mechanism of the intracellular killing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 macrophages activated by gamma interferon.

Authors:  Y Ouadrhiri; B Scorneaux; Y Sibille; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

9.  Characterization of Abcc4 gene amplification in stepwise-selected mouse J774 macrophages resistant to the topoisomerase II inhibitor ciprofloxacin.

Authors:  Béatrice Marquez; Geneviève Ameye; Coralie M Vallet; Paul M Tulkens; Hélène A Poirel; Françoise Van Bambeke
Journal:  PLoS One       Date:  2011-12-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.